| Literature DB >> 30457542 |
Xiaohong Pan, Jianmin Jiang, Qiaoqin Ma, Jiafeng Zhang, Jiezhe Yang, Wanjun Chen, Xiaobei Ding, Qin Fan, Zhihong Guo, Yan Xia, Shichang Xia, Zunyou Wu.
Abstract
On January 25, 2017, a physician from ZC Hospital in Hangzhou, China, reported to the Zhejiang Provincial Center for Disease Control and Prevention that a potential HIV outbreak might have occurred during lymphocyte immunotherapy (LIT) performed at the hospital on December 30, 2016. We immediately began investigating and identified the index case-patient as an LIT patient's husband who donated lymphocytes for his wife's LIT and later screened HIV-reactive. Subsequent contamination by a technician resulted in the potential exposure of 34 LIT patients. Acute HIV infection was diagnosed in 5 persons. Phylogenetic analysis confirmed that the HIV-1 gag, pol, and env gene sequences from the index and outbreak-related cases had >99.5% similarity. Rapid investigation and implementation of effective control measures successfully controlled the outbreak. This incident provides evidence of a lapse in infection control causing HIV transmission, highlighting the need for stronger measures to protect patients from infectious disease exposure.Entities:
Keywords: China; HIV; Human immunodeficiency virus; lymphocyte immunotherapy; nosocomial transmission; viruses
Mesh:
Substances:
Year: 2018 PMID: 30457542 PMCID: PMC6256388 DOI: 10.3201/eid2412.180117
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Timeline of HIV exposure and HIV diagnosis of the index case-patient, P0 (blue), and the HIV exposure of his wife, Mrs. P0 (orange), Hangzhou, China, November 27, 2016–January 24, 2017. CDC, Center for Disease Control and Prevention; LIT, lymphocyte immunotherapy; P, patient; WB, Western blot.
Figure 2Timeline of HIV exposure, symptoms, diagnosis, and treatment initiation for the 5 HIV-infected women during nosocomial HIV outbreak, Hangzhou, China, December 30, 2016–February 9, 2017. P1, purple; ART, antiretroviral therapy; LIT, lymphocyte immunotherapy; P, patient; WB, Western blot.
Interval between HIV exposure and follow-up HIV tests for the 37 persons followed up after initially screening HIV-nonreactive in investigation of nosocomial HIV outbreak, Hangzhou,China, 2016–2017*
| Potential contact | Days between HIV exposure and follow-up HIV tests | |||||||
|---|---|---|---|---|---|---|---|---|
| 1st test | 2nd test | 3rd test | 4th test | 5th test | 6th test | 7th test | 8th test | |
| Primary† | ||||||||
| Mrs. P0‡ | 24 | 29 | 45 | 68 | 103 | 130 | 191 | 464 |
| Q1 | 28 | 48 | 82 | |||||
| Q2 | 28 | 58 | 86 | 186 | ||||
| Q3 | 27 | 29 | 59 | 84 | 182 | |||
| Q4 | 28 | 58 | 86 | 192 | ||||
| Q5 | 28 | 45 | 86 | 192 | ||||
| Q6 | 28 | 56 | 94 | 188 | ||||
| Q7 | 27 | 28 | 57 | 99 | 211 | |||
| Q8 | 29 | 58 | 100 | 189 | ||||
| Q9 | 27 | 57 | 45 | 85 | ||||
| Q10 | 27 | 28 | 60 | 93 | 187 | |||
| Q11 | 28 | 64 | 106 | 202 | ||||
| Q12 | 29 | 55 | 83 | 185 | ||||
| Q13 | 27 | 29 | 58 | 89 | ||||
| Q14 | 27 | 35 | 62 | 92 | 199 | |||
| Q15 | 27 | 33 | 64 | 93 | 212 | |||
| Q16 | 27 | 45 | 93 | |||||
| Q17 | 27 | 33 | ||||||
| Q18 | 27 | 34 | 59 | 90 | 189 | |||
| Q19 | 27 | 33 | 63 | 91 | 187 | |||
| Q20 | 28 | 60 | 90 | 194 | ||||
| Q21 | 30 | 55 | 80 | 192 | ||||
| Q22 | 31 | 45 | 93 | 186 | ||||
| Q23 | 31 | 53 | 81 | 188 | ||||
| Q24 | 33 | 55 | 89 | 187 | ||||
| Q25 | 32 | 63 | 92 | 196 | ||||
| Q26 | 33 | 63 | 95 | 189 | ||||
| Q27 | 33 | 47 | 97 | 193 | ||||
| Q28 | 33 | 60 |
|
|
|
|
|
|
| Secondary§¶ | ||||||||
| P3’s husband | 7 | 30 | 57 | 97 | 182 | |||
| P4’s husband | 11 | 28 | 52 | 98 | 180 | |||
| P5’s husband | 2 | 18 | 25 | 32 | 60 | 196 | ||
| Infant P0 | 3 | 42 | 90 | 242 | ||||
| Infant P2 | 3 | 43 | ||||||
| Infant P4 | 1 | 44 | ||||||
*First HIV test was conducted using both nucleic acid testing and EIA. All subsequent HIV tests were conducted using EIA only. Blank cells indicate no further HIV test. EIA, enzyme immunoassay; LIT, lymphocyte immunotherapy; P, patient infected with HIV; Q, women who might have been exposed to HIV but were not infected. †Beginning of the time interval was counted from contaminated LIT at ZC Hospital on December 30, 2016. ‡Mrs. P0 is the wife of the index case-patient, P0. She is continuing to be followed once a year for at least 3 years since she discontinued antiretroviral therapy. Her most recent HIV test, on March 9, 2018, was again negative. §For husbands, beginning of the time interval was counted from the most recent sexual contact with the wife from the wife’s exposure on December 30, 2016, through the start of the investigation on January 25, 2017. Husbands received both serologic (4th-generation Ag/Ab EIA, Shanghai Kehua Bio-Engineering, Shanghai, China) and virologic testing (HIV-1 RNA, COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0, Roche, Branchburg, NJ, USA). ¶For infants, beginning of the time interval was counted as the date of birth. The first 3 HIV tests for infants were early infant diagnosis tests by a standard nucleic acid testing protocol. The fourth test for infant P0 was a 4th-generation Ag/Ab EIA.
Similarity of HIV genetic sequence of viral nucleic acid from the index case-patient and the 5 women infected by during nosocomial HIV outbreak, Hangzhou, China, 2016–2017
| Region | Sequence similarity, % | |||||
|---|---|---|---|---|---|---|
| Case-patient 1 | Case-patient 2 | Case-patient 3 | Case-patient 4 | Case-patient 5 | Mean | |
|
| 99.70 | 100.00 | 100.00 | 100.00 | 100.00 | 99.95 |
|
| 99.50 | 99.40 | 99.50 | 99.50 | 99.50 | 99.48 |
|
| 100.00 | 100.00 | 100.00 | 100.00 | 99.60 | 99.92 |
Figure 3Phylogenetic trees showing relationships between HIV-1 gene sequences from index case-patient and 5 women infected during nosocomial HIV outbreak, Zhejiang Province, China, 2016–2017, and reference sequences. Bootstrap values >90% only are shown for gag sequences (A), pol sequences (B), and env sequences (C). Triangles indicate index case-patient (P0) and 5 women found to have HIV infection (P1–5); dots indicate international reference sequences. Scale bars indicate nucleotide substitutions per site. P, patient.